Health & Medicine Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health & Medicine Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Glioblastoma
Vorinostat shows anti-cancer activity in recurrent gliomas
June 18th, 2007
North Central Cancer Treatment Group (NCCTG) researchers, based at Mayo Clinic (http://www.mayo.edu/) in Rochester, Minn., report that a novel application of the drug vorinostat shows activity in patients with recurrent glioblastoma multiforme. These findings were presented at the American Society of Clinical Oncology (http://www.asco.org/portal/site/ASCO) Annual Meeting by Eva Galanis, M.D. (http://mayoresearch.mayo.edu/mayo/research/staff/galanis_e.cfm), a Mayo Clinic oncologist and lead investigator of the study. Glioblastoma multiforme is a lethal primary brain tumor. The average survival of glioblastoma patients is 12-16 months. These tumors spread...
Source: Health & Medicine Week (2007-06-18)
|
